Skip to content

Effect of Hyperoxemia on Platelet Function in Healthy Volunteers

Effect of Hyperoxemia on Platelet Function in Healthy Volunteers

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01057420
Enrollment
50
Registered
2010-01-27
Start date
2009-04-30
Completion date
2010-05-31
Last updated
2010-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

Prospective, controlled, randomized crossover volunteer study to investigate the effect of hyperoxemia due to inhalation of oxygen (80% inspiratory fraction) via reservoir-face-mask on blood coagulation, especially platelet function, as measured by thrombelastography. According to results of basic animal and in vitro investigations, hyperoxemia may activate platelets by means of reactive oxygen species. This study aims at investigating a possible pro-coagulant effect of hyperoxemia in healthy volunteers. Additional studies on possible mechanisms are integrated. * Trial with medical device

Interventions

Inhalation of 80% oxygen via face mask

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* informed consent; no coagulation disorder or other illnesses; * non-smoker; * women: no pharmacological contraception, negative pregnancy test; * 25-45 years old; no medication; no acute or chronic airway problems; * for 24 hours before study: no extreme physical activity, no polyphenol-containing food (red wine, apples, cabbage, garlic); * for 48 hours: no caffeine-containing drinks, no dark chocolate.

Exclusion criteria

* Lack of one of the inclusion criteria; * allergy or incompatibility to substances/materials applied in the study; * very thin veins/arteries.

Design outcomes

Primary

MeasureTime frame
maximum amplitude in thrombelastography1 hour

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026